Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
J Cardiovasc Pharmacol ; 62(3): 285-97, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23676336

ABSTRACT

The mechanisms underlying the anti-inflammatory and antihypertensive effects of long-chain ω-3 polyunsaturated fatty acids (ω-3 PUFAs) are still unclear. The epoxides of an ω-6 fatty acid, arachidonic acid epoxyeicosatrienoic acids also exhibit antihypertensive and anti-inflammatory effects. Thus, we hypothesized that the major ω-3 PUFAs, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may lower the blood pressure and attenuate renal markers of inflammation through their epoxide metabolites. Here, we supplemented mice with an ω-3 rich diet for 3 weeks in a murine model of angiotensin-II-dependent hypertension. Also, because EPA and DHA epoxides are metabolized by soluble epoxide hydrolase (sEH), we tested the combination of an sEH inhibitor and the ω-3 rich diet. Our results show that ω-3 rich diet in combination with the sEH inhibitor lowered Ang-II, increased the blood pressure, further increased the renal levels of EPA and DHA epoxides, reduced renal markers of inflammation (ie, prostaglandins and MCP-1), downregulated an epithelial sodium channel, and upregulated angiotensin-converting enzyme-2 message and significantly modulated cyclooxygenase and lipoxygenase metabolic pathways. Overall, our findings suggest that epoxides of the ω-3 PUFAs contribute to lowering systolic blood pressure and attenuating inflammation in part by reduced prostaglandins and MCP-1 and by upregulation of angiotensin-converting enzyme-2 in angiotensin-II-dependent hypertension.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antihypertensive Agents/therapeutic use , Dietary Supplements , Disease Models, Animal , Epoxide Hydrolases/antagonists & inhibitors , Fatty Acids, Omega-3/therapeutic use , Hypertension, Renal/diet therapy , Angiotensin II , Angiotensin-Converting Enzyme 2 , Animals , Anti-Inflammatory Agents, Non-Steroidal/metabolism , Antihypertensive Agents/metabolism , Combined Modality Therapy , Enzyme Inhibitors/therapeutic use , Epithelial Sodium Channel Blockers/metabolism , Epithelial Sodium Channel Blockers/therapeutic use , Epithelial Sodium Channels/chemistry , Epithelial Sodium Channels/metabolism , Epoxide Hydrolases/chemistry , Epoxide Hydrolases/metabolism , Fatty Acids, Omega-3/metabolism , Hypertension, Renal/drug therapy , Hypertension, Renal/immunology , Inflammation Mediators/antagonists & inhibitors , Inflammation Mediators/metabolism , Kidney/drug effects , Kidney/immunology , Kidney/metabolism , Lipid Peroxidation/drug effects , Male , Mice , Mice, Inbred Strains , Peptidyl-Dipeptidase A/biosynthesis , Peptidyl-Dipeptidase A/genetics , Peptidyl-Dipeptidase A/metabolism , Random Allocation , Solubility
SELECTION OF CITATIONS
SEARCH DETAIL